drugset / Trial / NCT00293839

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

NCT00293839

Phase 3 Completed 790 enrolled Alza Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.

Timeline

Start
Primary completion
Completion
2002-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 10 mg Oral

Indications